Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
131,516,365
-
Number of holders
-
390
-
Total 13F shares, excl. options
-
112,239,402
-
Shares change
-
+2,870,343
-
Total reported value, excl. options
-
$19,027,485,774
-
Value change
-
+$501,915,844
-
Put/Call ratio
-
86%
-
Number of buys
-
191
-
Number of sells
-
-170
-
Price
-
$169.52
Significant Holders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) as of Q2 2021
474 filings reported holding ALNY - ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK as of Q2 2021.
ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) has 390 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 112,239,402 shares
of 131,516,365 outstanding shares and own 85.34% of the company stock.
Largest 10 shareholders include FMR LLC (17,631,728 shares), VANGUARD GROUP INC (10,497,694 shares), BAILLIE GIFFORD & CO (10,224,859 shares), WELLINGTON MANAGEMENT GROUP LLP (9,178,489 shares), BlackRock Inc. (8,696,403 shares), PRICE T ROWE ASSOCIATES INC /MD/ (5,524,678 shares), Dodge & Cox (5,414,001 shares), STATE STREET CORP (2,784,938 shares), JPMORGAN CHASE & CO (2,588,509 shares), and MORGAN STANLEY (1,882,650 shares).
This table shows the top 390 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.